Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT01055912
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 170 participants
- Sponsor
- CardioKine Inc.
- Registry
-
NCT01055912
-
- Other papers using this trial's data
- The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01055912. Randomized; triple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
- Condition
- Congestive Heart Failure
- Intervention (Drug)
- Lixivaptan
- Intervention (Drug)
- Placebo
- Lead sponsor
- CardioKine Inc.
- Collaborator
- Cardiokine Biopharma, LLC
Record details
- Record id
cardio:ct-nct01055912- Content hash
2a9630672b9590d6898b7cb74f1e5d985f5ec0739a05c68c0c75ed4728546b95